What Pfizer / AstraZeneca rerally meant to the M&A landscape

As is true in business so it is in life: just because someone really, really wants to be with you doesn’t mean you can play hard to get forever. After six-months of courting AstraZeneca, Pfizer announced that it had pulled its $118 billion offer and had no plans to attempt a hostile acquisition.

Advertisement